NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals, Inc. (NRXPW) Stock Overview
Explore NRx Pharmaceuticals, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
59.3M
P/E Ratio
-2.19
EPS (TTM)
$-6.25
ROE
1.13%
NRXPW Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of NRx Pharmaceuticals, Inc. (NRXPW) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 48.07, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $0.17.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -2.19 and a market capitalization of 59.3M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Technical Indicators
Company Profile
NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.
Jonathan C. Javitt
1201 Orange Street, Wilmington, DE
2017